Related Experiment Video
Updated: Feb 6, 2026

Large-Scale Multi-Omics Genome-Wide Association Studies Mo-GWAS: Guidelines for Sample Preparation and Normalization
Published on: July 27, 2021
Association study between multiple system atrophy and TREM2 p.R47H
Kotaro Ogaki1, Michael G Heckman1, Shunsuke Koga1
1Department of Neuroscience (K.O., S.K., Y.A.M, C.L., O.L.-B., R.L.W., A.I.S., S.F., S.G.Y., G.B., D.W.D., O.A.R.), Mayo Clinic, Jacksonville, FL; Department of Neurology (K.O.), Juntendo University Shizuoka Hospital, Izunokunishi, Shizuoka, Japan; Division of Biomedical Statistics and Informatics (M.G.H., E.R.V), Mayo Clinic, Jacksonville, FL; Department of Neurology (R.J.U., J.A.v.G., W.P.C., Z.K.W.), Mayo Clinic, Jacksonville, FL; Department of Neurology (P.A.L., W.S.), Mayo Clinic, Rochester, MN; Mayo Graduate School (O.A.R.), Neurobiology of Disease, Jacksonville, FL; and Department of Clinical Genomics (O.A.R.), Jacksonville, FL.
Objective:
The triggering receptor expressed on myeloid cells 2 (TREM2) p.R47H substitution (rs75932628) is a risk factor for Alzheimer disease (AD) but has not been well studied in relation to the risk of multiple system atrophy (MSA); the aim of this study was to evaluate the association between the TREM2 p.R47H variant and the risk of MSA.
Methods:
A total of 168 patients with pathologically confirmed MSA, 89 patients with clinically diagnosed MSA, and 1,695 controls were included. TREM2 p.R47H was genotyped and assessed for association with MSA. Positive results in the Taqman genotyping assay were confirmed by Sanger sequencing. The primary comparison involved patients with pathologically confirmed MSA and controls due to the definitive MSA diagnosis in the pathologically confirmed series.
Results:
We identified TREM2 p.R47H in 3 patients with pathologically confirmed MSA (1.79%), 1 patient with clinically diagnosed MSA (1.12%), and 7 controls (0.41%). Minimal AD pathology was observed for the pathologically confirmed MSA p.R47H carriers. For the primary comparison of patients with pathologically confirmed MSA and controls, risk of disease was significantly higher for p.R47H carriers (odds ratio [OR]: 4.39, p = 0.033). When supplementing the 168 pathologically confirmed patients with the 89 clinically diagnosed and examining the combined MSA series, the association with TREM2 p.R47H remained significant (OR: 3.81, p = 0.034).
Conclusions:
Our preliminary results suggest that the TREM2 p.R47H substitution may be a risk factor for MSA, implying a link to neuroinflammatory processes, especially microglial activation. Validation of this finding will be important, given our relatively small sample size; meta-analytic approaches will be needed to better define the role of this variant in MSA.
Insights
The TREM2 p.R47H variant, a known Alzheimer's risk factor, may also increase the risk for multiple system atrophy (MSA). This suggests a potential link between neuroinflammation and MSA development.
Area of Science:
- Neurogenetics
- Neurodegenerative Diseases
- Immunology
Background:
- The Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) p.R47H variant is a known risk factor for Alzheimer's disease.
- Its association with Multiple System Atrophy (MSA) risk has not been extensively studied.
- Understanding genetic risk factors for MSA is crucial for developing targeted therapies.
Purpose of the Study:
- To investigate the association between the TREM2 p.R47H variant and the risk of developing Multiple System Atrophy (MSA).
- To explore the potential role of TREM2 in the pathogenesis of MSA.
Main Methods:
- Genotyping of the TREM2 p.R47H variant in 168 pathologically confirmed MSA patients, 89 clinically diagnosed MSA patients, and 1,695 controls.
- Association analysis was performed, with positive findings confirmed by Sanger sequencing.
- Primary comparison utilized pathologically confirmed MSA cases and controls for definitive diagnosis.
Main Results:
- The TREM2 p.R47H variant was found in 1.79% of pathologically confirmed MSA patients and 0.41% of controls.
- Carriage of the TREM2 p.R47H variant was significantly associated with an increased risk of MSA (OR: 4.39, p=0.033).
- This association remained significant when including clinically diagnosed MSA patients (OR: 3.81, p=0.034).
Conclusions:
- Preliminary findings suggest the TREM2 p.R47H substitution may be a risk factor for MSA.
- This implies a potential role for neuroinflammatory processes, particularly microglial activation, in MSA.
- Further validation with larger sample sizes and meta-analyses is recommended to confirm these findings.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Bioavailability Study Design: Single Versus Multiple Dose Studies
Association Areas of the Cortex
Prefrontal Association Area: This area is located in the frontal lobe and is involved in planning, decision-making, and moderating social behavior. It connects with primary motor areas,...
Associative Learning
Classical conditioning, also known...
Multiple Allele Traits
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...

